Project Grant R43HD112277

Award Date 6/1/23
Completion Date 5/31/24
Dollars Obligated $385K
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Orlando, FL 32826, USA
Similar Awards
The University of North Carolina at Chapel Hill received a $100,000 Project Grant award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a digital therapeutic device and mobile application for patients with high-tone pelvic floor disorders. The award will support the creation of an interactive pelvic wand and accompanying smartphone app to enable patients to conduct targeted pelvic floor muscle physical therapy...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), is funding the development of an intravaginal, wearable medical device called "Violet" by Bold Type LLC. The Violet device is designed to provide pelvic floor muscle vibration and electrical nerve stimulation therapy for patients with high tone pelvic floor dysfunction, a major contributor...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,516,765 to the University of California, Los Angeles (UCLA) to develop and validate an innovative near-infrared spectroscopy (NIRS) technology for the quantitative assessment of pelvic floor muscle function in patients with myofascial pelvic pain (MPP). The research aims to establish NIRS as an effective, non-invasive,...
This Project Grant award of $384,923.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support the development of an innovative, girth-adjustable vaginal dilator with precise dilation monitoring. The primary goals are to improve patient pain management and adherence for the treatment of chronic pelvic floor disorders, which affect over 25 million women annually in the U.S. The key products to be...
The National Institute of Child Health and Human Development (NICHD) awarded Pelva Health Corporation a $328,496 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to develop a novel hydrogel film and applicator delivery system that helps mitigate pain experienced during sexual intercourse by women with gynecologic pain conditions, specifically vulvodynia and vestibulodynia. The goal is to create a non-pharmaceutical solution that reduces pressure on sensitive...
The Project Grant award R43HD115425 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) is supporting Theranova LLC, a veteran-owned medical device R&D company, to conduct a pilot clinical study evaluating the SOLESTIM neuromodulation system as a home-use treatment for dysmenorrhea (primary menstrual cramps). The $343,510 award will fund a 16-week,...
The National Institute of Child Health and Human Development (NICHD) awarded Madorra Inc., a woman-owned small business, a $1,514,498 SBIR Direct-to-Phase II Project Grant (CFDA 93.865) to develop an at-home, non-hormonal ultrasonic device for the treatment of vulvovaginal atrophy (VVA). VVA affects up to 90% of peri- and postmenopausal women, as well as many breast cancer survivors receiving estrogen-suppressing treatments. The project aims to 1) update the Madorra Therapy System design to...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $299,518 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to V-Flow Medical Inc. to develop a novel diagnostic catheter and modular stent system to treat pelvic venous insufficiency (PVI), a primary cause of chronic pelvic pain (CPP) in women. The project will utilize an ovine model to evaluate the safety and efficacy of V-Flow's catheter and stent system in improving clinical outcomes...
This federal Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the Research and Training in Complementary and Integrative Health program (CFDA 93.213), provides $562,735 to The Regents of the University of California, San Francisco (UCSF) to conduct a randomized controlled trial evaluating the feasibility and efficacy of a remotely delivered pelvic yoga program for women with chronic pelvic pain syndrome. The research aims to rigorously assess...
This Project Grant award of $6,154,752, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research aimed at understanding how menstrual pain and bladder hypersensitivity interact to promote chronic pelvic pain (CPP). The 3-year study, starting on September 17, 2024, will be conducted by Endeavor Health Clinical Operations, a non-profit research institute at Evanston Hospital. The project will...

A DEVICE TO TREAT HIGH-TONE PELVIC FLOOR DYSFUNCTION IN WOMEN - ABSTRACT BOLD TYPE IS DEVELOPING THE "SMARTWAND", AN INTERACTIVE, CONNECTED PELVIC FLOOR SYSTEM (DEVICE AND MOBILE APP) TO GUIDE PATIENTS THROUGH PELVIC FLOOR PHYSICAL THERAPY (PT) IN THE PRIVACY OF THEIR HOME. PT IS A HIGHLY EFFECTIVE AND FIRST-LINE TREATMENT FOR HIGH TONE PELVIC FLOOR DYSFUNCTION (HTPFD), A MAJOR CONTRIBUTOR TO CHRONIC PELVIC PAIN (CPP), AFFECTING UP TO 15% OF WOMEN IN THE UNITED STATES. DESPITE PROVEN EFFECTIVENESS, ONLY 20% OF WOMEN COMPLETE THE PT TREATMENT COURSE, WHICH INCLUDES A HOME EXERCISE COMPONENT WITH AN EXTERNAL AND INTERNAL EXERCISE REGIMEN. WOMEN REPORT LIMITATIONS IN CONTINUING PT AS TIME, COST, ACCESS TO THERAPY, THE LACK OF DIRECT FEEDBACK FROM THE HOME PROGRAM AND THE INABILITY TO MEASURE PROGRESS AT HOME. BOLD TYPE'S TEAM HAS DECADES OF PRODUCT DEVELOPMENT EXPERIENCE WITH MEDICAL DEVICES, QUALITY, AND REGULATORY AFFAIRS. WE HAVE DEVELOPED PROPRIETARY HARDWARE AND SOFTWARE DEVELOPMENT KITS THAT ALLOW US TO DESIGN AND IMPLEMENT MEDICAL DEVICES EFFICIENTLY BY LEVERAGING REUSABLE SUBSYSTEMS THAT ARE DESIGNED AND DOCUMENTED TO COMPLY WITH FDA REGULATIONS. TO MEET THE CRITICAL NEED FOR ACCESSIBLE AND IMPROVED PT, WE HYPOTHESIZE THAT: (1) AN ERGONOMIC WAND DESIGN WILL IMPROVE USABILITY, (2) AN INNOVATIVE SYSTEM FOR PERFORMING PT CAN BE DEVELOPED THAT PROVIDES GUIDANCE AND BIOFEEDBACK TO PHYSICAL THERAPISTS AND PATIENTS; AND (3) PATIENTS WILL BE ABLE TO EFFECTIVELY PERFORM PT USING THE GUIDANCE AND BIOFEEDBACK PROVIDED BY THE PLATFORM. WE PROPOSE THE FOLLOWING SPECIFIC AIMS FOR THIS PROJECT: 1) FINALIZE THE WAND DESIGN FROM THREE PRELIMINARY DESIGN PROTOTYPES USING HUMAN FACTORS VALIDATION TESTING. A FORMATIVE USABILITY EVALUATION OF THREE PRELIMINARY WAND PROTOTYPES WILL BE CONDUCTED IN 15 MECHANICAL WAND EXPERIENCED HTPFD PATIENTS TO IDENTIFY PREFERRED DESIGN FEATURES. WE WILL USE SIMULATED-USE TESTING UNDER THE SUPERVISION OF A PELVIC FLOOR PHYSICAL THERAPIST AND SYSTEMATICALLY COLLECT DATA FROM TEST PARTICIPANTS USING THE UNPOWERED DEVICE PROTOTYPE; 2) DEVELOP A WIRELESS, HANDHELD "SMARTWAND" AND MOBILE APP THAT (1) RECORDS PRESSURE AND LOCATION (DEPTH AND ORIENTATION) IN THE FEMALE PELVIS IN RELATION TO THE PELVIC FLOOR MUSCLES, (2) PROVIDES THE USER AUDIO AND VISUAL FEEDBACK ON WAND PRESSURE, POSITION, AND ORIENTATION, AND (3) TRANSFERS DATA TO A DATABASE FOR STORAGE AND ANALYSIS; AND 3) VALIDATE THE SYSTEM DEVELOPED IN SPECIFIC AIM 2 ON A GROUP OF 10 HEALTHY WOMEN AND 10 WOMEN WITH HTPFD. WOMEN >18 YEARS WILL BE RECRUITED BY GRACE PHYSICAL THERAPY AND THERAPISTS ASSIGNED TO PERFORM PRESSURE PAIN THRESHOLDS AND INSTRUCT ON WAND USE. THE SUCCESS METRIC FOR AIM 3 IS THAT WITH GUIDANCE FROM THE APP, THE PARTICIPANTS WILL BE ABLE TO PERFORM WAND EXERCISES WITH MINIMAL VARIANCE AS COMPARED TO MEASUREMENTS MADE BY THE PT (WITHIN 15% OF APPLIED PRESSURE, 5 DEGREES OF ANGLE/ORIENTATION AND WITHIN 8 MM OF INSERTION DEPTH).

Posted 5/29/23